Pritelivir: 10 Key Facts on the New Pill for Hard-to-Treat Herpes in Immunocompromised Adults

FDA approval of pritelivir (Hovilpri), the first helicase-primase inhibitor for refractory herpes simplex in immunocompromised adults: how it works, PRIOH-1 trial results, side effects and medicine interactions.

·

·

8–12 minutes

·

Edited by Joshua Adebanjo, RN

Pritelivir: New Pill for Resistant Herpes

The US Food and Drug Administration (FDA) has approved pritelivir, sold as Hovilpri, a new oral treatment for herpes simplex virus (HSV) sores of the skin and mucous membranes that have not responded to standard antiviral medicines in adults with weakened immune systems.

The approval was announced on 9 October 2026. Pritelivir is the first of a new class of antivirals called helicase-primase inhibitors, which work differently from medicines such as aciclovir and valaciclovir and remain active against many resistant strains of HSV-1 and HSV-2. In the phase 3 PRIOH-1 trial, 63% of people treated with pritelivir had complete healing of all lesions by day 28, compared with 34% of those given other treatments. Side effects were also less common. The medicine is expected to be available in the US before the end of 2026.

pritelivir

Imagine a 52-year-old man who had a stem cell transplant for leukaemia eight months ago. Since then, painful herpes sores around his mouth and genitals have kept coming back and now refuse to heal, despite courses of standard antiviral tablets. The alternative has been a drip treatment in hospital that can harm the kidneys. His transplant nurse explains that a new oral medicine has been approved in the US for exactly this situation. It works in a different way, so resistance to his previous tablets doesn’t matter. For someone who has already spent months in hospital, the idea of a tablet at home feels like a welcome relief.

What happened

On 9 October 2026, Asahi Kasei Therapeutics announced the FDA approval of pritelivir (Hovilpri) tablets, developed by Aicuris, for mucocutaneous HSV lesions that are refractory to standard antiviral treatment, with or without confirmed resistance, in immunocompromised adults.

Pritelivir is a helicase-primase inhibitor. Unlike nucleoside analogues such as aciclovir, it does not need to be activated by a viral enzyme called thymidine kinase, which is often changed in resistant viruses. This allows it to work against many strains that no longer respond to standard treatment.

Asahi Kasei will market the medicine in the US, with availability expected before the end of 2026.

10 key facts

  1. The FDA approved pritelivir (Hovilpri) in October 2026.
  2. It treats herpes sores that haven’t healed with standard antivirals.
  3. It is for adults with weakened immune systems.
  4. It is the first helicase-primase inhibitor approved.
  5. It works against many resistant HSV-1 and HSV-2 strains.
  6. In PRIOH-1, 63% healed fully by day 28 vs 34%.
  7. By day 42, 82% responded vs 42%.
  8. Side effects were less common than with comparison treatments.
  9. Some stomach acid medicines reduce how well it works.
  10. It is taken by mouth, unlike some alternatives given by drip.

The numbers at a glance

  • Approval announced: 9 October 2026
  • PRIOH-1 part C: 101 immunocompromised adults
  • Complete healing by day 28: 63% vs 34%
  • Lesion response by day 42: 82% vs 42%
  • Adverse reactions: 22% vs 54%
  • Stopped due to side effects: 2% vs 20%
  • Headache: 6% vs 4%

Why herpes can be hard to treat in people with weak immunity

Herpes simplex viruses cause cold sores and genital herpes. In most people, outbreaks are short and respond well to antiviral medicines such as aciclovir, valaciclovir and famciclovir.

In people with weakened immune systems, for example after organ or stem cell transplants, during chemotherapy, or with advanced HIV, herpes sores can be larger, more painful and last much longer. Repeated treatment increases the chance of the virus becoming resistant.

When standard medicines fail, options have included intravenous foscarnet or cidofovir, which can damage the kidneys and require hospital care, or topical treatments with limited effect.

Why this matters

Refractory herpes in immunocompromised people causes significant pain, risk of further infection and reduced quality of life. Existing alternatives have serious side effects.

Pritelivir offers an oral option with a different mechanism, a better healing rate in its trial and fewer side effects than the comparison treatments.

As more people live with weakened immunity due to transplants and cancer treatments, effective options for resistant infections become increasingly important.

What officials and experts said

Stacy Wheeler, chief executive of Asahi Kasei Therapeutics, said Hovilpri ‘offers a new oral treatment option for adult patients’ with a persistent, difficult-to-treat disease.

What this means for you

  • If you have a weakened immune system and herpes sores aren’t healing, tell your care team promptly.
  • Ask whether testing for resistance is needed.
  • Tell your team about all medicines, especially for stomach acid.
  • Take pritelivir exactly as prescribed.
  • Keep sores clean and avoid touching them.
  • Report headache or new symptoms.

What this means for nurses and health workers

Nurses in transplant, oncology and HIV care can help identify refractory herpes early and support safe treatment.

  • Monitor non-healing sores in immunocompromised patients.
  • Arrange swabs and resistance testing.
  • Review acid-reducing medicines and interactions.
  • Support oral care and pain relief.
  • Prevent secondary infection.
  • Educate patients on preventing spread.

The global picture

Resistant herpes infections are seen worldwide, mainly in specialist transplant, cancer and HIV services. Access to new treatments outside the US will depend on regulatory decisions in each country.

Medicine interactions

Medicines that reduce stomach acid can lower the amount of pritelivir absorbed. Some proton pump inhibitors should be avoided and others limited, and timing should be separated from H2 blockers and antacids. Pritelivir also affects a transporter called BCRP, which may raise levels of some other medicines. Always check with your pharmacist or care team.

The PRIOH-1 trial

The phase 3 PRIOH-1 trial compared pritelivir with the investigator’s choice of intravenous foscarnet, intravenous or topical cidofovir, or topical imiquimod in 101 immunocompromised adults. Pritelivir led to significantly more complete healing and fewer side effects.

Preventing herpes spread

Avoid kissing and oral or genital contact when sores are present, don’t share towels or lip products, and wash hands after touching sores.

Who is immunocompromised?

People with transplants, those having chemotherapy, people with advanced HIV, and those on strong immune-suppressing medicines are considered immunocompromised.

Caring for painful sores

Pain relief, keeping lesions clean and dry, and soothing mouth rinses can ease discomfort.

A new class of antivirals

Helicase-primase inhibitors block enzymes the virus needs to copy its DNA. Their different mechanism is why they work when older antivirals don’t.

Why early action matters

In people with weakened immune systems, herpes sores that persist can grow larger, become very painful, and allow bacteria or fungi to cause additional infections. Sores in the mouth and throat can make eating and drinking difficult, leading to weight loss and dehydration, while genital and anal sores can cause severe discomfort. Recognising early that a sore is not healing as expected allows the care team to take swabs, test for resistance and switch treatment sooner. Patients and carers can help by taking photos of sores to track changes, noting when they started, and reporting promptly if they are not improving after several days of standard treatment. Early action reduces suffering and the risk of complications.

Preventing herpes flares after a transplant or during cancer treatment

Many transplant and cancer programmes give preventive antiviral medicines to people at high risk of herpes reactivation, especially during periods of very low immunity. Taking these exactly as prescribed reduces flares. Good mouth care, using a soft toothbrush and gentle mouthwashes, helps protect the delicate lining of the mouth. Sun protection on the lips can reduce cold sore triggers. Stress, illness and fatigue can also trigger flares, so rest and good nutrition matter. If you notice tingling, burning or new blisters, contact your team early rather than waiting, as early treatment is more effective. Your nurse can explain which symptoms need same-day attention and who to call out of hours.

Pharmacists can help you plan the timing of all your medicines so that pritelivir works as well as possible, especially if you need treatment for indigestion or reflux.

Living with recurrent herpes

Repeated outbreaks can affect confidence, relationships and mental health. Talking openly with partners, using barrier protection and accessing counselling or support groups can help people cope. Remember that herpes is very common and manageable.

Support is available.

Myths and facts

Myth: Herpes always clears up quickly.
Fact: In people with weak immunity, sores can last weeks or months.

Myth: All antivirals work the same way.
Fact: Pritelivir uses a different mechanism.

Myth: Resistant herpes can only be treated in hospital.
Fact: Pritelivir is an oral option.

Myth: Herpes can’t be passed on when using treatment.
Fact: It can still spread; take precautions.

Questions and answers

What is pritelivir?

A new oral antiviral for refractory herpes in immunocompromised adults.

How does it work?

It blocks the helicase-primase enzyme the virus needs to copy itself.

How effective is it?

63% healed fully by day 28 in its main trial.

What are the side effects?

Headache was the most common.

Does it interact with other medicines?

Yes, especially stomach acid medicines.

When will it be available?

In the US before the end of 2026.

Is it for everyone with herpes?

No, it is for immunocompromised adults with refractory infection.

What happens next

Pritelivir is expected to become available in the US by the end of 2026. Regulators in other countries may review it. Research continues into its use in other situations.

Key takeaways

  • The FDA approved pritelivir (Hovilpri) in October 2026.
  • It is for adults with weakened immune systems.
  • It works against many resistant HSV-1 and HSV-2 strains.
  • By day 42, 82% responded vs 42%.
  • Some stomach acid medicines reduce how well it works.
  • It is taken by mouth, unlike some alternatives given by drip.

How we report health news

Nursing Media Network reports health news using official sources such as the World Health Organization, national public health agencies, medicines regulators and peer-reviewed research, which are linked at the end of each story. Figures in fast-moving stories, such as outbreaks, change quickly, so we state the date each number refers to. If you are reading this later, check the latest update from the official source before making decisions.

News reports describe what has happened across a population. They cannot tell you what is right for your own health. If a story raises questions about your treatment, symptoms or risk, speak to your nurse or healthcare provider before making any changes.

Staying informed without feeling overwhelmed

A constant stream of health headlines can leave people anxious or confused. It can help to choose one or two trusted sources and check them at set times, rather than scrolling throughout the day. Focus on what you can control, such as vaccinations, regular check-ups, healthy routines and knowing when to seek care. Talk about worries with family, friends or your nurse rather than keeping them to yourself, and take a break from news if it is affecting your sleep or mood. Being informed is useful; being overwhelmed is not.

Finding reliable health information

Health information online varies widely in quality. Prefer sources such as the World Health Organization, national health ministries, public health agencies, university hospitals and registered professional bodies. Be cautious with social media posts, miracle cures and products sold with promises that sound too good to be true.

If you read something that worries you or contradicts the advice you have been given, write it down and discuss it with your nurse or healthcare provider. They can explain how it applies to your own situation and help you separate evidence from rumour.

Questions to ask your nurse or healthcare provider

  • Are my herpes sores resistant to standard treatment?
  • Is pritelivir an option for me?
  • Do my other medicines interact with it?
  • How long will treatment last?
  • How can I prevent spreading herpes?
  • What should I do if sores don’t improve?

But aren’t herpes sores just a minor nuisance?

For most people, yes. But for people with weakened immunity, they can be severe and hard to treat, which is why new options matter.

Your next step: If you have a weakened immune system and herpes sores aren’t healing, contact your care team promptly to discuss testing and treatment.

Related: Herpes · Cold sores · Shingles · Neutropenia

Sources: Contagion Live, 10 October 2026; FDA: novel drug approvals 2026.

Joshua Ibukunoluwa Adebanjo

Founder & Editor-in-Chief

Joshua Ibukunoluwa Adebanjo

RN, RM, RPHN, BNSc (Obafemi Awolowo University)

Joshua is a registered nurse, midwife and public health nurse with clinical experience at Obafemi Awolowo University Teaching Hospitals Complex. He founded Nursing Media Network to give nurses worldwide trustworthy news, career guidance and a stronger public voice, and leads its editorial direction.

Full profile · Editorial policy · joshuadebanjo.com

Health information on Nursing Media Network is for education and does not replace advice from your own nurse or healthcare provider.

Leave a Reply

Most read

Discover more from Nursing Media Network

Subscribe now to keep reading and get access to the full archive.

Continue reading